UK markets close in 7 hours 52 minutes
  • FTSE 100

    7,131.96
    +26.24 (+0.37%)
     
  • FTSE 250

    23,360.11
    +70.46 (+0.30%)
     
  • AIM

    1,260.88
    +2.19 (+0.17%)
     
  • GBP/EUR

    1.1743
    +0.0017 (+0.15%)
     
  • GBP/USD

    1.3942
    +0.0027 (+0.19%)
     
  • BTC-GBP

    27,073.84
    -769.90 (-2.77%)
     
  • CMC Crypto 200

    923.10
    -20.34 (-2.16%)
     
  • S&P 500

    4,423.15
    +35.99 (+0.82%)
     
  • DOW

    35,116.40
    +278.24 (+0.80%)
     
  • CRUDE OIL

    70.29
    -0.27 (-0.38%)
     
  • GOLD FUTURES

    1,816.70
    +2.60 (+0.14%)
     
  • NIKKEI 225

    27,584.08
    -57.75 (-0.21%)
     
  • HANG SENG

    26,407.97
    +213.15 (+0.81%)
     
  • DAX

    15,667.98
    +112.90 (+0.73%)
     
  • CAC 40

    6,756.47
    +32.66 (+0.49%)
     

Transaction in own shares

·2-min read

Arix Bioscience PLC (ARIX)
22-Jul-2021 / 17:07 GMT/BST
Dissemination of a Regulatory Announcement, transmitted by EQS Group.
The issuer is solely responsible for the content of this announcement.

Arix Bioscience plc

 

Transaction in own shares

 

LONDON, 22 July 2021: Arix Bioscience plc ("Arix" or "the Company") (LSE:ARIX), a global venture capital company focused on investing in and building breakthrough biotech companies, today announces that it purchased the following number of its ordinary shares of 0.001 pence each on the London Stock Exchange from Jefferies International Limited as part of a buyback programme announced on 22 March 2021.

 

Date of purchase

22 July 2021

Aggregate number of shares purchased

18,000

Highest price paid per share

176.00p

Lowest price paid per share

176.00p

Average price paid per share

176.00p

 

Arix intends to retain the purchased shares in treasury.

Following settlement of the above purchase, Arix will have 130,988,800 ordinary shares of 0.001 pence each in issue (excluding 4,620,853 ordinary shares of 0.001p each held in treasury). This number represents the total voting rights in Arix and may be used by shareholders as the denominator for the calculations by which they can determine if they are required to notify their interest in, or a change to their interest in, the Company under the Financial Conduct Authority's Disclosure and Transparency Rules.

In accordance with Article 5(1)(b) of Regulation (EU) No. 596/2014 (as incorporated into UK domestic law by the European Union (Withdrawal) Act 2018), the schedule below contains detailed information of the individual trades made by Jefferies International Limited as part of the buyback programme.

[ENDS]

For more information on Arix, please contact:

 

Arix Bioscience plc

Charlotte Parry, Head of Investor Relations

+44 (0)20 7290 1072

charlotte@arixbioscience.com

 

 

Optimum Strategic Communications

Mary Clark, Manel Mateus

+44 (0)20 3922 1906

optimum.arix@optimumcomms.com

 

About Arix Bioscience plc

Arix Bioscience plc is a global venture capital company focused on investing in and building breakthrough biotech companies around cutting-edge advances in life sciences.

We collaborate with exceptional entrepreneurs and provide the capital, expertise and global networks to help accelerate their ideas into important new treatments for patients. As a listed company, we are able to bring this exciting growth phase of our industry to a broader range of investors. www.arixbioscience.com

 

 

 

Transaction Date

Transaction Time

Volume

Price (GBp)

Platform

Transaction Reference Number

22/07/2021

11:17:19

18,000

176.00

London Stock Exchange

00252854661TRLO1

 


ISIN:

GB00BD045071

Category Code:

POS

TIDM:

ARIX

LEI Code:

213800OVT3AHQCXNIX43

OAM Categories:

2.4. Acquisition or disposal of the issuer's own shares

Sequence No.:

118243

EQS News ID:

1221073


 

End of Announcement

EQS News Service

show this
show this
Our goal is to create a safe and engaging place for users to connect over interests and passions. In order to improve our community experience, we are temporarily suspending article commenting